Velenosi TJ, Fu AY, Luo S, Wang H, Urquhart BL
, 22 , 4104-4110, doi: Strohkamp, S., Gemoll, T., Humborg, S., Hartwig, S., Lehr, S., Freitag-Wolf, S., Becker, S., Franzn, B., Pries, R., Wollenberg, B., Roblick, U
The tirzepatide before and after results page shows outcomes from both branded and compounded protocols
Patients should not double up or take extra doses to compensate for the missed injection, as this increases the risk of gastrointestinal adverse effects including nausea, vomiting, and diarrhea
People with obesity are more likely to have cancer and cardiovascular disease, and recent research has shown that people who use GLP-1 analogues could have a lower risk of both
9,10 Additionally, GLP-1 RAs suppress glucagon secretion from the -cells in the pancreas, leading to decreased blood glucose levels